Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

Imago BioSciences will announce preliminary results from its Phase IIb clinical trial for myelofibrosis (MF) at the 25th European Hematology Association (EHA) Annual Congress that begins June 12, 2020 and is beginning to enroll patients for a Phase IIa trial targeting essential thrombocythemia (ET). In May, Imago also hit the milestones trigger a $26 million second tranche and recently hired a medical affairs and chief business officer and added a member of the board.